13.07.2015 Views

2010 BC Guide in Determining Fitness to Drive

2010 BC Guide in Determining Fitness to Drive

2010 BC Guide in Determining Fitness to Drive

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Chapter 11: Diabetes – HypoglycemiaBACKGROUND11.1 About diabetes and hypoglycemiaDiabetesDiabetes is a chronic and progressive disease characterized by hyperglycemia (high bloodglucose). It appears <strong>in</strong> two pr<strong>in</strong>cipal forms 3 : type 1 diabetes, formerly called <strong>in</strong>sul<strong>in</strong>-dependent diabetes mellitus (IDDM) or juvenilediabetes, and type 2 diabetes, formerly called non-<strong>in</strong>sul<strong>in</strong>-dependent diabetes mellitus (NIDDM) or adul<strong>to</strong>nsetdiabetes.Type 1 diabetes can occur at any age, but it primarily appears before age 30. Type 2 diabetesusually occurs <strong>in</strong> <strong>in</strong>dividuals over the age of 40. Type 1 and type 2 also differ <strong>in</strong> the underly<strong>in</strong>gdefect, and type of therapeutic control. Type 1 is characterized by the <strong>in</strong>ability <strong>to</strong> produce<strong>in</strong>sul<strong>in</strong> and often more marked fluctuations <strong>in</strong> blood glucose. Daily <strong>in</strong>sul<strong>in</strong> <strong>in</strong>jections are alwaysrequired <strong>to</strong> manage type 1 diabetes. Type 2 diabetes is characterized by an impaired ability <strong>to</strong>recognize and utilize <strong>in</strong>sul<strong>in</strong>, and eventually dim<strong>in</strong>ished <strong>in</strong>sul<strong>in</strong> production. Therapeutic controloften is achieved by diet alone or <strong>in</strong> comb<strong>in</strong>ation with oral antihyperglycemic agents 4 , but peoplewith type 2 diabetes whose blood glucose cannot be controlled <strong>in</strong> this way require treatment with<strong>in</strong>sul<strong>in</strong>.HypoglycemiaAnyone who requires treatment with <strong>in</strong>sul<strong>in</strong> is at risk of hypoglycemia. Those with type 2diabetes treated with <strong>in</strong>sul<strong>in</strong> secretagogues (oral medications that stimulate the secretion of<strong>in</strong>sul<strong>in</strong>) or metform<strong>in</strong> (an oral medication that enhances the effect of <strong>in</strong>sul<strong>in</strong>) also mayexperience hypoglycemia, although the frequency with this treatment is lower than with <strong>in</strong>sul<strong>in</strong>.Hypoglycemia may occur for a number of reasons, <strong>in</strong>clud<strong>in</strong>g reduced food <strong>in</strong>take, unusual levelof physical exertion, and alteration of <strong>in</strong>sul<strong>in</strong> dose.Hypoglycemia can result <strong>in</strong> two types of symp<strong>to</strong>ms, neurogenic (au<strong>to</strong>nomic) andneuroglycopenic.3 Other types of diabetes <strong>in</strong>clude gestational diabetes, other specific types (those due <strong>to</strong> genetic defects <strong>in</strong> β-cellfunction, genetic defects <strong>in</strong> <strong>in</strong>sul<strong>in</strong> action, diseases of the exocr<strong>in</strong>e pancreas, drug or chemical <strong>in</strong>duced diabetes,etc.), and pre-diabetes. These types of diabetes are less common than type 1 and type 2 diabetes and are notdiscussed <strong>in</strong> this chapter.4 Oral antihyperglycemics also may be referred <strong>to</strong> as oral hypoglycemics.85

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!